产品详情
查看大图

  • 产品名称：CRL-2558 PL45 人胰腺导管腺癌细胞

  • 产品型号：CRL-2558
  • 产品厂商：其它品牌
  • 产品文档：
你添加了1件商品 查看购物车
简单介绍：
简单介绍 CRL-2558 PL45 人胰腺导管腺癌细胞，原代细胞|细胞系|细胞株|菌种；细胞库管理规范，提供的细胞株背景清楚，提供参考文献和**培养条件！
详情介绍：

CRL-2558 PL45 人胰腺导管腺癌细胞 的详细介绍
CRL-2558 PL45 人胰腺导管腺癌细胞
ATCC® Number: CRL-2558™     Price:  
Designations: PL45
Depositors:  SE Kern
Biosafety Level: 1
Shipped: frozen
Medium & Serum: See Propagation
Growth Properties: adherent
Organism: Homo sapiens (human)
Morphology: epithelial
Source: Organ: pancreas 
Disease: ductal adenocarcinoma
Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
 
Oncogene: BRCA2 +; DPC4 +; K-ras +; p53 +
DNA Profile (STR): Amelogenin: X 
CSF1PO: 12 
D13S317: 12 
D16S539: 9,12 
D5S818: 13 
D7S820: 8,9 
THO1: 6,9.3 
TPOX: 11 
vWA: 16
Age: *****
Gender: male
Ethnicity: White
Comments: PL45 is a pancreatic adenocarcinoma epithelial cell line derived in 1992 from a primary tumor removed from the pancreas of a man with poorly differentiated pancreatic adenocarcinoma of ductal origin. 
The MTS1 gene on chromosome 9p21 encodes the p16 inhibitor of cyclinD/CDK4 complexes. PL45 cells have a wild-type p16 gene. [50656] 
This gene is transcriptionally silenced and methylated in PL45 cells. 
PL45 cells have a wild-type cyclin-dependent kinase (CDK4) gene. 
Both the PL45 and the Panc 10.05 cell lines exhibit a K-ras oncogene mutation at codon 12 where a GGT --> GAT mutation resulted in substitution of aspartic acid for glycine. [50655] [50656] 
The line expresses wild-type DPC4 and BRCA2 genes. 
The line has a p53 gene mutation at codon 255 where an ATC --> AAC mutation resulted in substitution of asparagine for isoleucine. 
The PL45 cell line was derived from the same patient as the Panc 10.05 cell line (ATCC CRL-2547).
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Dulbecco's Modified Eagle's Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Atmosphere: air, 95%; carbon dioxide (CO2), 5% 
Temperature: 37.0°C
Subculturing: Protocol:
  1. Remove and discard culture medium.
  2. Briefly rinse the cell layer with 0.25% (w/v) Trypsin- 0.53 mM EDTA solution to remove all traces of serum that contains trypsin inhibitor.
  3. Add 2.0 to 3.0 ml of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).
    Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37°C to facilitate dispersal.
  4. Add 6.0 to 8.0 ml of complete growth medium and aspirate cells by gently pipetting.
  5. Add appropriate aliquots of the cell suspension to new culture vessels.
  6. Incubate cultures at 37°C.

Subcultivation Ratio: A subcultivation ratio of 1:2 to 1:6 is recommended 
Medium Renewal: Every 2 to 3 days
Preservation: Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO 
Storage temperature: liquid nitrogen vapor phase
Related Products: Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2002
recommended serum:ATCC 30-2020
derived from same individual:ATCC CRL-2547
References: 50655: Jaffee EM, et al. Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. Cancer J. Sci. Am. 4: 194-203, 1998. PubMed: 9612602
50656: Caldas C, et al. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat. Genet. 8: 27-32, 1994. PubMed: 7726912
51521: Su GH, et al. ACVR1B (ALK4, activin receptor type 1B) gene mutations in pancreatic carcinoma. Proc. Natl. Acad. Sci. USA 98: 3254-3257, 2001. PubMed: 11248065
ATCC® Number: CRL-2558™ Price: $329.00 
Designations: PL45 
Depositors: SE Kern 
Biosafety Level: 1 
Shipped: frozen 
Medium & Serum: See Propagation 
Growth Properties: adherent 
Organism: Homo sapiens (human) 
Morphology: epithelial


Source: Organ: pancreas 
Disease: ductal adenocarcinoma 
Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location. 

Oncogene: BRCA2 +; DPC4 +; K-ras +; p53 + 
DNA Profile (STR): Amelogenin: X 
CSF1PO: 12 
D13S317: 12 
D16S539: 9,12 
D5S818: 13 
D7S820: 8,9 
THO1: 6,9.3 
TPOX: 11 
vWA: 16 
Age: ***** 
Gender: male 
Ethnicity: White 
Comments: PL45 is a pancreatic adenocarcinoma epithelial cell line derived in 1992 from a primary tumor removed from the pancreas of a man with poorly differentiated pancreatic adenocarcinoma of ductal origin. 
The MTS1 gene on chromosome 9p21 encodes the p16 inhibitor of cyclinD/CDK4 complexes. PL45 cells have a wild-type p16 gene. [50656] 
This gene is transcriptionally silenced and methylated in PL45 cells. 
PL45 cells have a wild-type cyclin-dependent kinase (CDK4) gene. 
Both the PL45 and the Panc 10.05 cell lines exhibit a K-ras oncogene mutation at codon 12 where a GGT --> GAT mutation resulted in substitution of aspartic acid for glycine. [50655] [50656] 
The line expresses wild-type DPC4 and BRCA2 genes. 
The line has a p53 gene mutation at codon 255 where an ATC --> AAC mutation resulted in substitution of asparagine for isoleucine. 
The PL45 cell line was derived from the same patient as the Panc 10.05 cell line (ATCC CRL-2547). 
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Dulbecco's Modified Eagle's Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Atmosphere: air, 95%; carbon dioxide (CO2), 5% 
Temperature: 37.0°C 
Subculturing: Protocol: 
1.Remove and discard culture medium.
2.Briefly rinse the cell layer with 0.25% (w/v) Trypsin- 0.53 mM EDTA solution to remove all traces of serum that contains trypsin inhibitor.
3.Add 2.0 to 3.0 ml of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).
Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37°C to facilitate dispersal.
4.Add 6.0 to 8.0 ml of complete growth medium and aspirate cells by gently pipetting.
5.Add appropriate aliquots of the cell suspension to new culture vessels.
6.Incubate cultures at 37°C.

Subcultivation Ratio: A subcultivation ratio of 1:2 to 1:6 is recommended 
Medium Renewal: Every 2 to 3 days 
Preservation: Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO 
Storage temperature: liquid nitrogen vapor phase 
Related Products: Recommended medium (without the additional supplements or serum described under ATCC

沪公网安备 31010902002433号